Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialRobert I. Haddad, Marshall R. Posner, Anne O’Neill et al.|The Lancet Oncology|2013Cited by 748
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II StudyGlenn J. Hanna, Jochen H. Lorch, Naifa L. Busaidy et al.|Clinical Cancer Research|2018Cited by 125
Identifying Breast Cancer Patients at High Risk for Bone MetastasesMarco Colleoni, Andrea Veronesi, Martin F. Fey et al.|Journal of Clinical Oncology|2000Cited by 125
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Anne O’Neill et al.|Clinical Cancer Research|2021Cited by 104
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)Sewanti Limaye, Robert I. Haddad, Sarah Riley et al.|Oral Oncology|2013Cited by 59